[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"angiofollicular-lymph-node-hyperplasia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:angiofollicular-lymph-node-hyperplasia":54},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":20,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":33,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":5},"100271815",false,"NCT02817997","International Registry for Patients With Castleman Disease","ACCELERATE (Advancing Castleman Care With an Electronic Longitudinal Registry, E-Repository, And Treatment\u002FEffectiveness Research): An International Registry for Patients With Castleman Disease","ACCELERATE","Inclusion Criteria:\n\n* Person of any age\n* Have a reference pathology report suggesting \"Castleman disease\" not limited to cutaneous involvement only that can be uploaded\n* Be able to provide electronic informed consent, as per local regulations\n* Deceased patients may also be enrolled when a reference pathology report suggesting \"Castleman disease\" can be supplied or when the ART is able to locate and upload such a pathology report.\n\nExclusion Criteria:\n\n* Because this registry is designed to provide as wide a picture of routine clinical practice as possible, inclusion criteria are set deliberately wide and there are no exclusion criteria.","ALL",{"count":18,"type":19},1000,"ESTIMATED","10 Years","OBSERVATIONAL","The purpose of this study is to collect clinical, laboratory, and patient survey data from patients with Castleman disease to improve understanding, diagnosis, and treatment of the disease. Funding source - FDA OOPD.",[24,25,26,27,28,29,30,31,32],"Castleman Disease","Castleman's Disease","Giant Lymph Node Hyperplasia","Angiofollicular Lymph Hyperplasia","Angiofollicular Lymph Node Hyperplasia","Angiofollicular Lymphoid Hyperplasia","GLNH","Hyperplasia, Giant Lymph Node","Lymph Node Hyperplasia, Giant",[34,35,36,37,38,39,25,27,40,41],"patient registry","ACCELERATE study","CD","MCD","iMCD","Castleman","multicentric Castleman's disease","multicentric Castleman disease","RECRUITING","2026-02-27",{"date":45,"type":46},"2026-03-03","ACTUAL",{"date":48,"type":4},"2016-10",{"date":50,"type":19},"2027-09",{"name":52,"class":53},"University of Pennsylvania","OTHER",""]